metricas
covid
Buscar en
Revista Colombiana de Psiquiatría
Toda la web
Inicio Revista Colombiana de Psiquiatría Avances en la investigación de inmunoterapias contra las drogas de abuso
Journal Information
Vol. 39. Issue S.
Pages 213S-223S (January 2010)
Share
Share
Download PDF
More article options
Vol. 39. Issue S.
Pages 213S-223S (January 2010)
Artículos
Full text access
Avances en la investigación de inmunoterapias contra las drogas de abuso
Research Advances in the Immunotherapies of Addictions
Visits
1210
Iván D. Montoya1,
Corresponding author
imontoya@mail.nih.gov

Correspondencia: Iván D. Montoya, Pharmacotherapies and Medical Consequences Grants, National Institute on Drug Abuse, 6001 Executive Blvd., Bethesda, MD 20892, Maryland, Estados Unidos
1 Médico. MPH. Clinical director, Pharmacotherapies and Medical Consequences Grants, National Institute on Drug Abuse. Bethesda, Maryland, Estados Unidos
This item has received
Article information
Resumen
Introducción

Las terapias inmunológicas, ya sea con vacunas (inmunización activa) o con anticuerpos (inmunización pasiva), se están investigando activamente para el manejo de las complicaciones del consumo de drogas de abuso.

Objetivo

Revisar el estado actual del desarrollo en la investigación de inmunoterapias contra nicotina, cocaína, heroína, metanfetamina y fenciclidina (PCP), con énfasis en los aspectos clínicos de cada una de ellas.

Método

Revisión de la literatura sobre el tema.

Resultados

Hasta el momento, las inmunoterapias evaluadas en humanos parecen ser seguras desde el punto de vista médico y con eficacia esperanzadora. Por este mecanismo se previene la activación de los mecanismos de refuerzo cerebral asociados con los efectos adictivos de la droga y, eventualmente, la extinción de la adicción.

Conclusión

En teoría, las vacunas también podrían ser útiles en la prevención del desarrollo de la adicción al igual que para prevenir las recaídas del uso de drogas. Los anticuerpos monoclonales parecen ser útiles en el tratamiento de las sobredosis de drogas, porque pueden prevenir los efectos neurotóxicos de las drogas al bloquear su acceso al cerebro. Actualmente, se están investigando vacunas contra la cocaína, heroína, metanfetamina y nicotina. Igualmente se están investigando anticuerpos monoclonales contra la cocaína, metanfetamina, nicotina y PCP.

Palabras clave:
inmunoterapia
vacunas
drogadicción
tratamiento
Abstract
Introduction

Immunological therapies, either with vaccines (active immunization) or with antibodies (passive immunization), are being actively investigated in the management of complications of drug abuse.

Objetive

To review the current state of research development of immunotherapies against nicotine, cocaine, heroin, methamphetamine and phencyclidine (PCP) with an emphasis on the clinical aspects.

Method

Review the literature about the topic.

Results

So far, immunotherapies evaluated in humans appear to be safe from a medical standpoint and effective. This mechanism prevents the activation of brain reinforcement mechanisms associated with the addictive effects of drugs and, eventually, the extinction of the drug addiction.

Conclusion

In theory, vaccines could also be useful in preventing the development of addiction as well as to prevent the relapse of drug use. Currently, vaccines are being investigated against cocaine, heroin, methamphetamine and nicotine. Likewise, monoclonal antibodies are being investigated against cocaine, methamphetamine, nicotine and phencyclidine (PCP).

Key words:
Immunotherapy
vaccines
drug addiction
treatment
Full text is only aviable in PDF
Referencias
[1]
ID Montoya, F Vocci.
Novel medications to treat addictive disorders.
Curr Psychiatry Rep, 10 (2008), pp. 392-398
[2]
KF Bonese, BH Wainer, FW Fitch, RM Rothberg, CR Schuster.
Changes in heroin self-administration by a rhesus monkey after morphine immunisation.
Nature, 252 (1974), pp. 708-710
[3]
I Montoya.
Inmunoterapias para adicción a drogas.
Adicciones, 20 (2008), pp. 111-115
[4]
SM Owens.
Antibodies as pharmacokinetic and metabolic modifiers of neurotoxicity.
NIDA Res Monogr, 173 (1997), pp. 259-272
[5]
BM Kinsey, DC Jackson, FM Orson.
Anti-drug vaccines to treat substance abuse.
Immunol Cell Biol, 87 (2009), pp. 309-314
[6]
T Kosten, SM Owens.
Immunotherapy for the treatment of drug abuse.
Pharmacol Ther, 108 (2005), pp. 76-85
[7]
AY Moreno, KD Janda.
Immunopharmacotherapy: vaccination strategies as a treatment for drug abuse and dependence.
Pharmacol Biochem Behav, 92 (2009), pp. 199-205
[8]
DK Hatsukami, LF Stead, PC Gupta.
Tobacco addiction.
Lancet, 371 (2008), pp. 2027-2038
[9]
EH Cerny, T Cerny.
Vaccines against nicotine.
Hum Vaccin, 5 (2009), pp. 200-205
[10]
Trial watch: Xenova's TA-NlC vaccine shows promise.
Expert Rev Vaccines, 3 (2004), pp. 386
[11]
CE Heading.
Drug evaluation: CYT-002-NicQb, a therapeutic vaccine for the treatment of nicotine addiction.
Curr Opin Investig Drugs, 8 (2007), pp. 71-77
[12]
CE Heading.
NicVAX (Nabi Biopharmaceuticals).
IDrugs, 6 (2003), pp. 1178-1181
[13]
DK Hatsukami, S Rennard, D Jorenby, M Fiore, J Koopmeiners, VA de, G Horwith, PR Pentel.
Safety and immunogenicity of a nicotine conjugate vaccine in current smokers.
Clin Pharmacol Ther, 78 (2005), pp. 456-467
[14]
ID Montoya, DJ McCann.
Drugs of abuse: management of intoxication and antidotes.
EXS, 100 (2010), pp. 519-541
[15]
TR Kosten, D Biegel.
Therapeutic vaccines for substance dependence.
Expert Rev Vaccines, 1 (2002), pp. 363-371
[16]
BA Martell, FM Orson, J Poling, E Mitchell, RD Rossen, T Gardner, et al.
Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial.
Arch Gen Psychiatry, 66 (2009), pp. 1116-1123
[17]
M Sofuoglu, TR Kosten.
Novel approaches to the treatment of cocaine addiction.
CNS Drugs, 19 (2005), pp. 13-25
[18]
BS Fox, KM Kantak, MA Edwards, KM Black, BK Bollinger, AJ Botka, et al.
Efficacy of a therapeutic cocaine vaccine in rodent models.
Nat Med, 2 (1996), pp. 1129-1132
[19]
D Gao, DL Narasimhan, J Macdonald, R Brim, MC Ko, DW Landry, et al.
Thermostable variants of cocaine esterase for long-time protection against cocaine toxicity.
Mol Pharmacol, 75 (2009), pp. 318-323
[20]
AB Norman, MK Norman, WR Buesing, MR Tabet, VL Tsibulsky, WJ Ball.
The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats.
J Pharmacol Exp Ther, 328 (2009), pp. 873-881
[21]
S Paula, MR Tabet, CD Farr, AB Norman, WJ Ball Jr.
Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody.
J Med Chem, 47 (2004), pp. 133-142
[22]
MR Carrera, GF Kaufmann, JM Mee, MM Meijler, GF Koob, KD Janda.
Treating cocaine addiction with viruses.
Proc Natl Acad Sci USA, 101 (2004), pp. 10416-10421
[23]
B Anton, A Salazar, A Flores, M Matus, R Marin, JA Hernandez, P Leff.
Vaccines against morphine/heroin and its use as effective medication for preventing relapse to opiate addictive behaviors.
Hum Vaccin, 5 (2009), pp. 214-229
[24]
KA Byrnes-Blake, EM Laurenzana, RD Landes, WB Gentry, SM Owens.
Monoclonal IgG affinity and treatment time alters antagonism of (+)-methamphetamine effects in rats).
Eur J Pharmacol, 521 (2005), pp. 86-94
[25]
WB Gentry, D Ruedi-Bettschen, SM Owens.
Development of active and passive human vaccines to treat methamphetamine addiction.
Hum Vaccin, 5 (2009 20), pp. 206-213
[26]
DE McMillan, WC Hardwick, M Li, MG Gunnell, FI Carroll, P Abraham, SM Owens.
Effects of murine-derived anti-methamphetamine monoclonal antibodies on (+)-methamphetamine self-administration in the rat.
J Pharmacol Exp Ther, 309 (2004), pp. 1248-1255
[27]
JS Hardin, WD Wessinger, GR Wenger, JW Proksch, EM Laurenzana, SM Owens.
A single dose of monoclonal anti-phencyclidine IgG offers long-term reductions in phencyclidine behavioral effects in rats.
J Pharmacol Exp Ther, 302 (2002), pp. 119-126
[28]
EM Laurenzana, MG Gunnell, WB Gentry, SM Owens.
Treatment of adverse effects of excessive phencyclidine exposure in rats with a minimal dose of monoclonal antibody.
J Pharmacol Exp Ther, 306 (2003), pp. 1092-1098
[29]
SM Owens, M Gunnell, EM Laurenzana, JL Valentine.
Dose- and time-dependent changes in phencyclidine metabolite covalent binding in rats and the possible role of CYP2D1.
J Pharmacol Exp Ther, 265 (1993), pp. 1261-1266
[30]
JL Valentine, SM Owens.
Antiphencyclidine monoclonal antibody therapy significantly changes phencyclidine concentrations in brain and other tissues in rats.
J Pharmacol Exp Ther, 278 (1996), pp. 717-724

Conflicto de interés: el autor manifiesta que no tiene ningún conflicto de interés en este artículo

Copyright © 2010. Asociación Colombiana de Psiquiatría
Article options